Lucid Capital analyst Elemer Piros initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $20 price target Coya is developing a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, the analyst tells investors in a research note. The firm sees an unmet need in amyotrophic lateral sclerosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics announces issuance of new U.S. patent for IL-2
- Coya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
- Coya Therapeutics Reports Q1 2025 Financial Results
- Coya Therapeutics reports Q1 EPS (44c), consensus (12c)
- Promising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline Potential